Clinical Trial Update: Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing the effect of empagliflozin, an SGLT2 inhibitor, on postprandial hypoglycemia in patients with dumping syndrome after gastric…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dumping Syndrome
• Hypoglycemia

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Dumping Syndrome, Hypoglycemia, Reactive | Phase 4 | Status: COMPLETED